While in vivo CAR-T therapies eliminate complex ex vivo manufacturing, they introduce a new critical variable: the patient's own immune system. The therapy's efficacy relies on modifying T-cells within the body, but each patient's immune status is different, especially after prior treatments. This makes optimizing and standardizing the dose a significant challenge compared to engineered cell therapies.

The hype around in-vivo CAR-T overlooks that it's a more complex form of gene therapy. It relies on the same delivery vectors (AAVs, LNPs) that have caused patient deaths and off-target effects like liver concentration in simpler gene therapies, suggesting a difficult path to success.

The field is moving from 7-10 day CAR-T manufacturing processes to just 3-5 days. This shift preserves the T-cells' fitness and less-differentiated state. Although the process yields fewer total cells, their increased potency means a smaller, more effective dose can be administered to the patient, representing a major evolution in strategy.

The belief that CAR-T is safer in autoimmunity than in cancer due to lower B-cell burden is being questioned. New data suggests macrophages in autoimmune patients are "primed" to overreact to T-cell activation, amplifying inflammatory cytokine release and creating unique, severe toxicity risks.

Developing CAR T-cell therapies for solid tumors is difficult because many tumor-associated antigens are also expressed on normal tissues. This creates a significant risk of "on-target, off-tumor" effects, causing severe toxicity. Mitigating this risk, for instance with engineered "kill switches," is as crucial as preserving the therapy's efficacy.

The manufacturing process for Brexicel CAR-T in ALL differs from other products like Axicel. It isolates T-cells first to avoid contamination from circulating leukemia blasts. This crucial step prevents the T-cells from becoming over-activated or exhausted before they are even reinfused into the patient, preserving their potency.

Early data from an in vivo CAR-T therapy suggests a paradigm shift is possible. By engineering T-cells directly inside the patient with a simple infusion, this approach could eliminate the need for leukapheresis and external manufacturing, completely disrupting the current cell therapy model.

While in vivo CAR-T could eliminate complex manufacturing, it lacks the safety guardrails of ex vivo methods. Clinicians cannot monitor the effective dose, count viral integrations, or guarantee that only T cells are engineered, posing significant risks of uncontrolled off-target effects.

The success of CAR-T therapy hinges on the quality of the patient's own lymphocytes. Procuring T-cells earlier in the disease course, before they become exhausted from numerous prior therapies, results in a higher proportion of naive T-cells, leading to better CAR-T cell manufacturing and clinical outcomes.